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Purpose/objective(s): Stereotactic body radiation therapy (SBRT) is emerging as 
a minimally invasive alternative to brachytherapy to deliver highly conformal, dose- 
escalated radiation therapy (RT) to the prostate. SBRT alone may not adequately cover 
the tumor extensions outside the prostate commonly seen in unfavorable prostate can-
cer. External beam radiation therapy (EBRT) with high dose rate brachytherapy boost is 
a proven effective therapy for unfavorable prostate cancer. This study reports on early 
prostate-specific antigen and prostate cancer-specific quality of life (QOL) outcomes in a 
cohort of unfavorable patients treated with intensity-modulated radiation therapy (IMRT) 
and SBRT boost.
Materials/methods: Prostate cancer patients treated with SBRT (19.5 Gy in three frac-
tions) followed by fiducial-guided IMRT (45–50.4 Gy) from March 2008 to September 2012 
were included in this retrospective review of prospectively collected data. Biochemical 
failure was assessed using the Phoenix definition. Patients completed the expanded 
prostate cancer index composite (EPIC)-26 at baseline, 1 month after the completion 
of RT, every 3 months for the first year, then every 6 months for a minimum of 2 years.
results: One hundred eight patients (4 low-, 45 intermediate-, and 59 high-risk) with 
median age of 74  years completed treatment, with median follow-up of 4.4  years. 
Sixty-four percent of the patients received androgen deprivation therapy prior to the 
initiation of RT. The 3-year actuarial biochemical control rates were 100 and 89.8% for 
intermediate- and high-risk patients, respectively. At the initiation of RT, 9 and 5% of men 
felt their urinary and bowel function was a moderate to big problem, respectively. Mean 
Abbreviations: ADT, androgen deprivation therapy; AUA, American Urological Association; CTC, common toxicity criteria; 
CTV, clinical target volume; EPIC, expanded prostate cancer index composite; GI, gastrointestinal; GTV, gross target volume; 
GU, genitourinary; IMRT, intensity-modulated radiation therapy; LUTS, lower urinary tract symptoms; PTV, planning target 
volume; QOL, quality of life; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
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inTrODUcTiOn
Prostate cancer has been shown to have a unique radiobiology 
resulting in a high sensitivity to fractionation (1). Analysis of 
clinical outcomes suggests that the α/β ratio for prostate cancer 
is approximately 1.5 Gy, rendering the tumor more biologically 
susceptible to large radiation fractions (2). Radiation dose esca-
lation for prostate cancer has been shown to provide decreased 
biochemical failure rates and improved local control (3, 4).
High dose rate (HDR) brachytherapy, with its ability to 
deliver highly conformal large doses per fraction, has been used 
as a boost following external beam radiotherapy (EBRT) in the 
treatment of patients with intermediate- and high-risk prostate 
cancer with promising results (5). When compared to low dose 
rate (LDR) brachytherapy, its greater flexibility in dose delivery 
allows for improved coverage of extracapsular extension (ECE) 
and seminal vesicle invasion (SVI) (6, 7). Supplemental EBRT 
treats the prostate and seminal vesicles with a margin to encom-
pass adjacent microscopic disease. Recent studies have illustrated 
5-year biochemical control rates of 89–93 and 69–83% for 
intermediate- and high-risk prostate cancer patients, respectively 
(8–11). However, the administration of HDR brachytherapy is 
an invasive procedure requiring anesthesia and hospitalization, 
with potential risk of adverse events for elderly prostate cancer 
patients.
In an effort to provide an alternative method of dose escala-
tion, stereotactic body radiation therapy (SBRT) is emerging 
as an alternative radiation therapy (RT) technique to deliver 
dose-escalated radiation to the prostate as a boost (12, 13). SBRT 
delivers highly conformal large radiation dose fractions via hun-
dreds of non-isocentric beams to target volumes with precision 
(<1 mm) and steep dose gradients. In addition, SBRT incorpo-
rates a real-time tracking system that corrects the targeting of 
the therapeutic beam during treatment allowing for correction of 
intra-fraction motion. This allows for a reduction in the planning 
target volume (PTV) and, thus, minimizes radiation exposure 
to critical surrounding organs during treatment (14) resulting 
in a comparable toxicity profile to conventionally fractionated 
radiotherapy, despite higher doses per fraction (15, 16).
Currently, there are limited data to suggest that any particular 
treatment for early-stage prostate cancer is superior to another 
(17), therefore making the toxicity and side effect profile of 
an effective treatment critically important when choosing an 
intervention (18). Prostate cancer-specific quality of life (QOL) 
questionnaires are commonly utilized to assess these side 
effects, particularly the function and bother experienced by a 
patient posttreatment. The function domain measures the direct 
function and dysfunction of the urinary and bowel systems, 
while the bother domain measures a patient’s distress to the 
functional detriment of the urinary and bowel secondary to RT 
(18). Although it is necessary to evaluate functional decrements, 
bother may be of more importance when assessing patients’ 
QOL outcomes (18).
In this study, we present the 2-year QOL outcomes of 108 
unfavorable prostate cancer patients treated with a combination of 
fiducial-directed intensity-modulated radiation therapy (IMRT) 
and SBRT boost with particular attention given to urinary/bowel 
function and bother.
MaTerials anD MeThODs
Patient selection
Patients eligible for inclusion in this study had histologically 
confirmed localized adenocarcinoma of the prostate treated 
with fiducial-guided IMRT and SBRT boost. Exclusion criteria 
included baseline prostate-specific antigen (PSA) >40  ng/ml, 
clinically involved lymph nodes, distant metastasis on imaging 
or bone scan, prior pelvic radiotherapy, and/or prior radical 
prostatectomy. Patient selection was accomplished by retro-
spective review of data that were prospectively collected in our 
institutional database. Institutional IRB approval was obtained 
for this study.
Treatment Planning and Delivery
Stereotactic Body Radiation Therapy
Our SBRT methods have been described in detail previously (12). 
In brief, patients had four to six gold fiducials placed into the 
prostate prior to treatment planning. Patients underwent mag-
netic resonance imaging (MRI) 7 days after fiducial placement, 
followed by non-contrast simulation CT scan with 1.25 mm slice 
thickness. Both scans were performed with an empty bladder, and 
patients were advised to adhere to a low-gas, low-motility diet at 
least 5 days before imaging and treatment delivery. Patients took 
nothing by mouth the night prior to simulation, and an enema 
was administered 1–2 h before imaging and treatment. Fused MR 
and CT scan images were then used for treatment planning.
EPIC urinary and bowel function and bother scores exhibited transient declines, with 
subsequent return to near baseline. At 2 years posttreatment, 13.7 and 5% of men felt 
their urinary and bowel function was a moderate to big problem, respectively.
conclusion: At 3-year follow-up, biochemical control was favorable. Acute urinary and 
bowel symptoms were comparable to conventionally fractionated IMRT and brachyther-
apy. Patients recovered to near their baseline urinary and bowel function by 2  years 
posttreatment. A combination of IMRT with SBRT boost is well tolerated with minimal 
impact on prostate cancer-specific QOL.
Keywords: prostate cancer, sBrT, cyberKnife, iMrT, ePic, igrT
TaBle 1 | Dose targets and constraints for supplemental sBrT treatment 
planning.
19.50 gy plan constraints
PTV V (19.5 Gy) ≥ 95%
Rectum V (19.5 Gy) < l cc
V (100%) < 5%
V (90%) < 10%
V (80%) < 20%
V (75%) < 25%
V (50%) < 50%
Bladder V (19.5 Gy) < 5 cc
V (100%) < 10%
V (50%) < 40%
Membranous urethra V (18 Gy) < 50%
TaBle 2 | Patient characteristics and treatment.
no. of patients  
(N = 108)
(%)
Age (years) Median 74 (55–92)
Race White 51 (47.2)
Black 45 (41.7)
Other 12 (11.1)
Pre-txt PSA (ng/ml) Median 9.1 (0.86–39.8)
T-stage <T2a 50 (46.3)
T2a–T2c 57 (52.8)
≥T3 1 (0.9)
Gleason score 6 (3 + 3) 10 (9.3)
7 (3 + 4; 4 + 3) 55 (50.9)
8 (3 + 5; 4 + 4) 26 (24.1)
9 (4 + 5; 5 + 4) 17 (15.7)
Risk groups 
(D’Amico’s)
Low 4 (3.7)
Intermediate 45 (41.7)
High 59 (54.6)
IMRT dose 45 Gy 84 (77.8)
50.4 Gy 21 (19.4)
Other 3 (2.8)
ADT Yes 70 (63.6)
α1A inhibitor 43 (39.8)
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The clinical target volume (CTV) included the prostate, areas 
of radiographic ECE, and the proximal seminal vesicles to the 
point where the left and right seminal vesicles separate. The 
SBRT-PTV equaled the CTV expanded 3  mm posteriorly and 
5 mm in all other dimensions. The rectum, bladder, and membra-
nous urethra were contoured and evaluated. Treatment planning 
utilized Multiplan (Accuray Inc., Sunnyvale, CA, USA) inverse 
treatment planning for the course of SBRT. The target doses and 
dose constraints to critical surrounding anatomic structures have 
been described previously (12) and are summarized in Table 1.
Patients were treated with a SBRT prescription dose of 19.5 Gy 
to the PTV, which was delivered in three fractions of 6.5 Gy over 
3–5 days using the CyberKnife Radiosurgical System (Accuray). 
The volume of the PTV receiving 19.5 Gy was at least 95%. The 
prescription isodose line was limited to >75%; the maximum pro-
static urethra dose was limited to 133% of the prescription dose. 
Target position was verified multiple times during each treatment 
using paired, orthogonal X-ray images with a minimum of three 
properly placed fiducials (19).
Intensity-Modulated Radiation Therapy
Patients initiated IMRT the week following SBRT. The CTV for 
IMRT included the prostate, areas of radiographic ECE, and the 
proximal seminal vesicles. The IMRT-PTV included a margin of 
1.0 cm around the CTV, except at the rectal interface, where a 
margin of 0.5 cm was added. The pelvic nodes were not treated. 
Daily doses of 1.8 Gy were delivered to PTV 5 days a week to a 
total dose of 45–50.4  Gy in 25–28 fractions. Eclipse planning 
system was utilized to design an inverse-planned course of 
IMRT. Daily image guidance was performed by matching gold 
fiducials. The minimum target dose constraint to the PTV was 
98% and the maximum target dose constraint was 105% of the 
dose. In the delivery of IMRT, 100% of the PTV was to receive 
at least 95% of the prescription dose, and 5% of the volume was 
to receive no more than 105% of the prescription dose. For the 
bladder and rectum, the maximum dose constraint limit was 
50 Gy, the full-volume dose constraint limit was 30 Gy and no 
part of either volume received more than 55.5 Gy. Dose to the 
femoral heads was limited to 45 Gy. The overall prescription dose 
to the PTV corresponded to a tumor equivalent dose in 2  Gy 
fractions (EQD2) of approximately 90  Gy assuming an alpha/
beta ratio of 1.5.
Pretreatment assessment, Follow-up, 
and statistical analysis
Prostate-specific antigen levels were obtained and prostate 
cancer-specific QOL questionnaires were administered prior 
to the first SBRT treatment, 1  month after the completion of 
RT, every 3  months for the first year posttreatment, and every 
6  months thereafter, for a minimum of 2  years. The expanded 
prostate cancer index composite (EPIC)-26 was used to evaluate 
urinary and bowel function and bother (17).
Differences in ongoing QOL scores were assessed and 
compared to baseline utilizing Wilcoxon signed rank test. The 
EPIC survey consisted of function and bother domains. The 
function domain measures the direct function and dysfunction 
of the urinary and bowel systems, while the bother domain 
measures a patient’s displeasure to the functional detriment 
secondary to RT. EPIC scores range from 0 to 100, with higher 
values representing a more favorable health-related QOL. The 
minimally important difference (MID) to assess for change in 
QOL scores was set as half a SD below baseline (20). Analysis 
of the QOL data included all time points that had at least an 
80% patient response rate, which was up to 24 months for all 
QOL measures.
resUlTs
Patients
From March 2008 to September 2012, 108 prostate cancer 
patients were treated per our institutional IMRT plus SBRT 
protocol. Table 2 provides a summary of patient characteristics. 
The median patient age was 74 years (range, 55–92 years). Similar 
numbers of White and Black patients were treated. The median 
pretreatment PSA was 9.1  ng/ml (range, 0.9–39.8  ng/ml). By 
D’Amico classification, 4 patients were low-, 45 intermediate-, 
and 59 high-risk. Seventy-eight percent of the patients were 
TaBle 4 | Quality of life (QOl) domain scores over time.
1 month 3 months 12 months 24 months
change sD change sD change sD change sD
EPIC-GU irritat./obstruct. −8.2a 16.8 −2.6 13.9 −1.3 16.7 −1.3 16.4
EPIC-GU incontinent −4.6a 15.4 −1.9 14.5 −3.4a 16.1 −4.0a 18.32
EPIC-bowel −5.9a 17.4 −2.3 13.7 −4.3a 17.0 −2.9a 16.1
EPIC, expanded prostate cancer index composite.
aStatistically significantly different from baseline (start).
FigUre 1 | actuarial biochemical control for the intermediate-risk 
group and high-risk group.
TaBle 3 | Pretreatment quality of life (QOl) scores.
Mean sD MiD
EPIC-GU irritat./obstruct. 86.5 13.8 6.9
EPIC-GU incontinent 92.2 12.6 6.3
EPIC-bowel 93.1 14.6 7.3
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treated with an IMRT dose of 45 Gy in 25 fractions. Androgen 
deprivation therapy (ADT) was administered to 63.6% of patients 
for a median duration of 6 months (range, 3–36 months).
The median follow-up was 4.4  years (range, 2.1–6.8  years). 
There were nine biochemical failures per the Phoenix definition 
(21), occurring in one intermediate-risk patient and eight high-
risk patients at a median of 36 months (range, 18–48 months). 
Three of the five post-failure prostate biopsies were positive for 
recurrent cancer. The corresponding 3-year actuarial biochemical 
control rates were 100 and 89.8% for intermediate- and high-risk 
patients, respectively (Figure 1). No patient died from prostate 
cancer during follow-up.
Quality of life
Baseline EPIC summary scores are shown in Table 3 and mean 
changes in EPIC summary scores from baseline to 2-year follow-
up are shown in Table  4. The EPIC scored urinary domain 
was stratified into two sub-domains: irritation/obstruction 
and incontinence. The mean urinary irritation/obstruction 
function score declined transiently at 1  month posttreatment 
(mean change from baseline, −8.2, p <  0.0001) and returned 
to baseline by 3 months post-RT (mean change from baseline, 
−2.6) (Table 4; Figure 2A). A second late decline in this function 
domain occurred at 9 months (mean change from baseline, −4.2, 
p = 0.17) with recovery by 12 months (p = 0.49). Only the decline 
at 1 month was statistically significant and met the threshold for 
clinically significant change (MID =  6.9). The EPIC irritation/
obstruction function domain nearly returned to baseline by 
24 months post-RT (mean change from baseline, −1.3, p = 0.55).
Baseline irritative and obstructive urinary symptoms were 
common in this cohort of elderly men (Table 5). The most both-
ersome baseline symptoms were weak stream (moderate to big 
problem in 6%) and frequency (moderate to big problem in 12%) 
(Table 5). At 1 month post-RT, 9 and 21% of patients reported 
moderate to big problems with weak stream and frequency, 
respectively. A second late increase in irritative/obstructive 
symptoms occurred at 9 months with 22% of patients reporting a 
moderate to big problem with urinary frequency.
The baseline EPIC urinary incontinence score and its mean 
changes from baseline to 2-year follow-up are shown in Tables 2 
and 3. The mean score acutely declined at 1  month post-RT 
(mean change from baseline, −4.6, p = 0.02) and returned to near 
baseline by 3 months (mean change from baseline, −1.9, p = 0.13) 
(Table 4; Figure 2B). This change was statistically significant but 
of borderline clinical significance (MID =  6.4). EPIC urinary 
incontinence scores showed a second late protracted decline over 
the next 2 years. At 2 years post-RT, the mean summary score 
decreased from a baseline of 92.2 to 88.2 (mean change from 
baseline, −4.0) (Table  4; Figure  2B). This change was statisti-
cally significant (p = 0.02), but of borderline clinical significance 
(MID = 6.4).
Baseline urinary incontinence was uncommon in this patient 
cohort (Table  5). Prior to RT, 3% of patients reported leaking 
greater than once per day and 5% reported frequent dribbling or 
no control at all (Table 5). However, only 1% reported pad usage 
prior to RT. At 2 years post-RT, 6, 4, and 5% of patients reported 
incontinence based on the definitions of leaking greater than one 
time per day, frequent dribbling, and pad usage.
The baseline EPIC bowel summary score is shown in Table 3, 
and mean changes in EPIC bowel summary scores from base-
line to 2-year follow-up are shown in Table 4. The mean bowel 
function score transiently declined from baseline to a nadir at 
1 month post-RT (mean change from baseline, −5.9, p = 0.0001) 
FigUre 2 | average ePic domain scores at baseline and following iMrT plus sBrT boost for prostate cancer. Shown are plots for: (a) EPIC urinary 
irritation/obstruction domain, (B) EPIC urinary incontinence domain, and (c) EPIC bowel domain. The thresholds for clinically significant changes in scores 
(½ SD above and below the baseline) are marked with dashed lines. IPSS scores range from 0 to 35 with higher values representing worsening urinary symptoms. 
EPIC scores range from 0 to 100 with higher values representing a more favorable health-related QOL. Thresholds for clinically significant changes in scores (½ SD 
above and below the baseline) are marked with dashed lines. EPIC scores range from 0 to 100 with higher values representing a more favorable health-related QOL.
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with some recovery by 3 months (mean change from baseline, 
−2.3, p = 0.09) (Table 4; Figure 2C). A second decline occurred 
at 6 months (mean change from baseline, −3.5, p = 0.007) and 
remained low at 2  years posttreatment (mean change from 
baseline, −2.9, p = 0.014). From 6 to 24 months, the change in 
bowel function from baseline was statistically significant but of 
borderline clinical significance (MID = 7.3).
Baseline proctitis symptoms were uncommon in our patients 
(Table 5). All proctitis symptoms except rectal pain increased at 
1 month post-RT. The most bothersome symptoms were bowel 
urgency and frequency. At 1 month post-RT, 8 and 7% of patients 
reported moderate to big problems with bowel urgency and fre-
quency, respectively. Bother with proctitis symptoms remained 
elevated throughout the 12  months post-RT with moderate to 
big overall bowel problem reaching its peak at 12% at 9 months 
post-RT. By 18  months post-RT, the percentage of patients 
with moderate to big bowel problems had returned to baseline 
(Table 5).
DiscUssiOn
Long-term patient survival is common after treatment for 
prostate cancer; therefore QOL is of paramount importance 
when selecting treatment options for patients. Outcome 
satisfaction, more closely related to bother than function, 
has been associated with long-term QOL (18). In an effort 
to further improve patient-reported outcomes following 
RT in the treatment of unfavorable prostate cancer, SBRT is 
emerging as viable alternative RT technique to HDR brachy-
therapy for boost delivery. SBRT delivers highly conformal 
large radiation dose fractions with dosimetric analysis sug-
gesting that adequate dose is delivered to areas of potential 
ECE and the proximal seminal vesicles, most commonly seen 
in unfavorable patients (22). Although prospective studies 
are needed to confirm long-term tumor control, currently 
reported data illustrate that early biochemical control rates in 
unfavorable patients treated with a combination of IMRT and 
SBRT boost are comparable to results from studies of patients 
receiving HDR brachytherapy boost (8, 10, 11, 16). In studies 
of HDR boost treatment, 3-year biochemical control rates for 
 intermediate- and high-risk patients range from 90 to 95% 
and 75 to 92%, respectively (8–11). This high biochemical 
 relapse-free survival rate has been reproduced in our study 
with the utilization of SBRT boost, with a 3-year biochemical 
control rate for intermediate- and high-risk patients at 100 and 
89.8%, respectively (Figure 1).
TaBle 5 | Percentage of patients reporting specific levels of distress or dysfunction.
Baseline
n = 106
1 month
n = 98
3 months
n = 97
6 months
n = 101
9 months
n = 92
12 months
n = 95
18 months
n = 92
24 months
n = 97
Urinary function
Irritation or obstruction
Dysuriaa 1 4 2 5 8 5 2 4
Hematuriaa 0 1 0 2 2 2 2 0
Weak streama 6 9 8 4 5 6 2 3
Frequencya 12 21 11 14 22 15 13 11
Incontinence
Leaking >l time per day 3 2 4 4 8 4 8 6
Frequent dribbling/no control 5 6 2 3 4 2 2 4
Any pad use 1 5 3 4 4 3 4 5
Leaking problema 1 0 3 2 4 0 4 4
Overall urinary problema 9 15 10 11 15 15 13 14
Bowel function
Urgencya 3 8 8 11 10 8 7 6
Frequencya 3 7 6 9 3 6 5 6
Fecal incontinencea 1 4 2 2 3 5 3 4
Bloody stoolsa 1 4 0 0 0 3 2 2
Rectal paina 6 4 0 2 4 2 1 2
Overall bowel problema 5 8 5 9 12 10 3 5
IMRT, intensity-modulated radiation therapy; SBRT, stereotactic body radiation therapy.
aCalculated based on item being “a moderate” or “big problem” on the EPIC QOL survey.
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In the first 2  years posttreatment, impacts on urinary and 
bowel QOL were minimal. Our QOL results are comparable 
to recent studies comparing patients who underwent single-
modality treatment with SBRT (23–28), radical prostatectomy, 
definitive EBRT, or brachytherapy (18). In our study, despite 
two-thirds of patients being treated with ADT, prostate-specific 
QOL scores remained high, demonstrating minimal impact of 
treatment-related side effects.
In this study, EPIC scores for bowel function and bother 
initially declined posttreatment but demonstrated recovery from 
symptoms by a 2-year follow-up (Table 3). A similar pattern of 
decline and recovery was witnessed for urinary function and 
bother (Table  3), with the exception of urinary incontinence 
(Figure  2B). Long-term urinary incontinence has been dem-
onstrated to increase at, and after, 2  years posttreatment using 
many treatment modalities, including protons, conventionally 
fractionated EBRT (both 3-D conformal RT and IMRT), and 
prostatectomy (29–32). The long-term trend of increasing 
urinary incontinence with time demonstrated in these reports 
demonstrates the importance of continuing follow-up on this 
study’s patient cohort to determine the impact of possible long-
term urinary functional detriment and bother. However, the 
minimally invasive combination of IMRT with SBRT boost is 
well tolerated among prostate cancer patients and still compares 
favorably with these alternative treatment modalities within the 
first 2 years posttreatment.
Until recently, there were limited data supporting the safety 
and efficacy of such SBRT monotherapy in the intermediate-risk 
population. Current publications by multiple single institutions 
used SBRT monotherapy regimens of 35–40 Gy, delivered to the 
prostate in four to five fractions, for intermediate-risk patients. 
Additionally, a pooled analysis from a multi-institutional con-
sortium has shown a favorable 5-year biochemical disease-free 
survival of 84% in intermediate-risk patients (33, 34). Following 
the publication, these papers and the analysis of our own results, 
it is now our policy to treat intermediate-risk patients with SBRT 
alone.
For high-risk patients, there remains a concern that the tight 
clinical margins required to limit the normal tissue doses to the 
rectum with SBRT may not be adequate to treat the extent of 
ECE. While the planned posterior margin for SBRT is 3 mm, the 
actually treated posterior margin is commonly limited to 2 mm 
or less to maintain rectal tolerance (1 cc < 36 Gy) (7, 22). In these 
patients, the risk of ECE beyond 2 mm is approximately 40–70% 
(35). In many high-risk patients, the SVI extends beyond the 
proximal seminal vesicles (36) and distal seminal vesicle motion 
cannot be accounted for by intraprostatic fiducials (37). Thus, 
we await the mature results of ongoing trials treating high-risk 
patients with SBRT alone prior to recommending it for all but well 
selected high-risk patients (38).
Currently, it is our policy to not include pelvic node irradia-
tion in the treatment of high-risk patients. Two randomized trials 
have been published questioning the benefit of treating pelvic 
lymph nodes in these patients (39, 40). A prior study with SBRT 
plus or minus conventional pelvic RT has shown significantly 
higher bowel toxicity associated with pelvic node treatment (41). 
Whether the use of pelvic IMRT can reduce bowel toxicity and 
improve the therapeutic ratio in select patients is an area of cur-
rent investigation (13).
Although this study illustrates favorable QOL outcomes 
to support the utilization of SBRT boost for the treatment of 
prostate cancer, it does have several limitations as a result of 
the retrospective nature of the study. However, patients, in our 
study, were accrued consecutively, and all data were collected 
prospectively in a centralized database. The analysis of QOL 
outcomes were a combined majority of intermediate- and high-
risk prostate cancer patients, stratifying data for each risk group 
was not performed.
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cOnclUsiOn
A combination of fiducial-guided IMRT and hypofractionated 
SBRT is well tolerated for the treatment of clinically localized 
prostate cancer, despite the delivery of dose-escalated radiation. 
Early PSA results suggest a biochemical control comparable to 
a combination of EBRT and HDR brachytherapy for intermedi-
ate- and high-risk prostate cancer patients. In the first 2  years 
posttreatment, impacts on urinary and bowel bother were mini-
mal. Patients recovered to their baseline urinary/bowel QOL by 
2 years following treatment.
aUThOr cOnTriBUTiOns
CM, M-AK, and RC are lead authors who participated in manu-
script drafting, table/figure creation, and manuscript revision. 
LC and TY aided in data collection and table/figure creation. SL 
and EB are the dosimetrists who contributed dosimetric data and 
figures. BC, AS, KH, SS, AD, and JL are senior authors who aided 
in drafting the manuscript and manuscript revision. SC is the cor-
responding author who initially developed the concept, drafted, 
and revised the manuscript. All authors read and approved the 
final manuscript.
reFerences
1. Fowler JF. Sensitivity analysis of parameters in linear-quadratic radiobiologic 
modeling. Int J Radiat Oncol Biol Phys (2009) 73:1532–7. doi:10.1016/j.
ijrobp.2008.11.039 
2. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of pros-
tate carcinoma. Int J Radiat Oncol Biol Phys (1999) 43:1095–101. doi:10.1016/
S0360-3016(98)00438-6 
3. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et  al. 
Randomized trial comparing conventional-dose with high-dose conformal 
radiation therapy in early-stage adenocarcinoma of the prostate: long-term 
results from proton radiation oncology group/American College of Radiology 
95-09. J Clin Oncol (2010) 28:1106–11. doi:10.1200/JCO.2009.25.8475 
4. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term 
survival and toxicity in patients treated with high-dose intensity modulated 
radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 
(2013) 85:686–92. doi:10.1016/j.ijrobp.2012.05.023 
5. Khor R, Duchesne G, Tai KH, Foroudi F, Chander S, Van Dyk S, et al. Direct 
2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs 
external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol 
Biol Phys (2013) 85:679–85. doi:10.1016/j.ijrobp.2012.07.006 
6. Stock RG, Lo YC, Gaildon M, Stone NN. Does prostate brachytherapy treat 
the seminal vesicles? A dose-volume histogram analysis of seminal vesicles 
in patients undergoing combined PD-103 prostate implantation and external 
beam irradiation. Int J Radiat Oncol Biol Phys (1999) 45:385–9. doi:10.1016/
S0360-3016(99)00209-6 
7. Patel AB, Waterman FM, Dicker AP. A detailed examination of the difference 
between planned and treated margins in 125I permanent prostate brachyther-
apy. Brachytherapy (2003) 2:223–8. doi:10.1016/j.brachy.2003.09.002 
8. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate 
intensity-modulated brachytherapy with external beam radiotherapy for 
prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat 
Oncol Biol Phys (2005) 61:1306–16. doi:10.1016/j.ijrobp.2004.08.014 
9. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, 
et  al. Long-term outcome by risk factors using conformal high-dose-rate 
brachytherapy (HDR-BT) boost with or without neoadjuvant androgen 
suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 
58:1048–55. doi:10.1016/j.ijrobp.2003.08.003 
10. Phan TP, Syed AM, Puthawala A, Sharma A, Khan F. High dose rate 
brachytherapy as a boost for the treatment of localized prostate cancer. J Urol 
(2007) 177:123–7. doi:10.1016/j.juro.2006.08.109 discussion 127 
11. Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, 
et al. Dose escalation using conformal high-dose-rate brachytherapy improves 
outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys (2002) 
53:316–27. doi:10.1016/S0360-3016(02)02733-5 
12. Oermann EK, Slack RS, Hanscom HN, Lei S, Suy S, Park HU, et al. A pilot 
study of intensity modulated radiation therapy with hypofractionated 
 stereotactic body radiation therapy (SBRT) boost in the treatment of 
 intermediate- to high-risk prostate cancer. Technol Cancer Res Treat (2010) 
9:453–62. doi:10.1177/153303461000900503 
13. Lin YW, Lin LC, Lin KL. The early result of whole pelvic radiotherapy and 
stereotactic body radiotherapy boost for high-risk localized prostate cancer. 
Front Oncol (2014) 4:278. doi:10.3389/fonc.2014.00278 
14. Webb S. Conformal intensity-modulated radiotherapy (IMRT) delivered by 
robotic linac-testing IMRT to the limit? Phys Med Biol (1999) 44:1639–54. 
doi:10.1088/0031-9155/44/7/305 
15. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate can-
cer: five-year outcomes. Radiat Oncol (2011) 6:3. doi:10.1186/1748-717X-6-3 
16. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radio-
therapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat 
(2010) 9:575–82. doi:10.1177/153303461000900605 
17. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, 
et al. Biochemical outcome after radical prostatectomy, external beam radia-
tion therapy, or interstitial radiation therapy for clinically localized prostate 
cancer. JAMA (1998) 280:969–74. doi:10.1001/jama.280.11.969 
18. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, 
et  al. Quality of life and satisfaction with outcome among prostate-cancer 
survivors. N Engl J Med (2008) 358:1250–61. doi:10.1056/NEJMoa074311 
19. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion 
of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol 
Phys (2008) 72:236–46. doi:10.1016/j.ijrobp.2008.04.051 
20. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health- 
related quality of life: the remarkable universality of half a standard deviation. 
Med Care (2003) 41:582–92. doi:10.1097/00005650-200305000-00007 
21. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, 
et  al. Defining biochemical failure following radiotherapy with or without 
hormonal therapy in men with clinically localized prostate cancer: recom-
mendations of the RTOG-ASTRO Phoenix Consensus Conference. Int 
J Radiat Oncol Biol Phys (2006) 65:965–74. doi:10.1016/j.ijrobp.2006.04.029 
22. Ju AW, Wang H, Oermann EK, Sherer BA, Uhm S, Chen VJ, et  al. 
Hypofractionated stereotactic body radiation therapy as monother-
apy for intermediate-risk prostate cancer. Radiat Oncol (2013) 8:30. 
doi:10.1186/1748-717X-8-30 
23. Chen LN, Suy S, Wang H, Bhagat A, Woo JA, Moures RA, et  al. Patient-
reported urinary incontinence following stereotactic body radiation therapy 
(SBRT) for clinically localized prostate cancer. Radiat Oncol (2014) 9:148. 
doi:10.1186/1748-717X-9-148 
24. Gurka MK, Chen LN, Bhagat A, Moures R, Kim JS, Yung T, et al. Hematuria 
following stereotactic body radiation therapy (SBRT) for clinically localized 
prostate cancer. Radiat Oncol (2015) 10:44. doi:10.1186/s13014-015-0351-6 
25. Arscott WT, Chen LN, Wilson N, Bhagat A, Kim JS, Moures RA, et  al. 
Obstructive voiding symptoms following stereotactic body radiation therapy 
for prostate cancer. Radiat Oncol (2014) 9:163. doi:10.1186/1748-717X-9-163 
26. Rana Z, Cyr RA, Chen LN, Kim BS, Moures RA, Yung TM, et al. Improved 
irritative voiding symptoms 3 years after stereotactic body radiation therapy 
for prostate cancer. Front Oncol (2014) 4:290. doi:10.3389/fonc.2014.00290 
27. Joh DY, Chen LN, Porter G, Bhagat A, Sood S, Kim JS, et al. Proctitis following 
stereotactic body radiation therapy for prostate cancer. Radiat Oncol (2014) 
9:277. doi:10.1186/s13014-014-0277-4 
28. Bhattasali O, Chen LN, Woo J, Park JW, Kim JS, Moures R, et al. Patient-reported 
outcomes following stereotactic body radiation therapy for clinically localized 
prostate cancer. Radiat Oncol (2014) 9:52. doi:10.1186/1748-717X-9-52 
29. Coen JJ, Paly JJ, Niemierko A, Weyman E, Rodrigues A, Shipley WU, et al. 
Long-term quality of life outcome after proton beam monotherapy for 
localized prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82:e201–9. 
doi:10.1016/j.ijrobp.2011.03.048 
8Mercado et al. IMRT with SBRT Boost for Prostate Cancer
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 114
30. Miller DC, Sanda MG, Dunn RL, Montie JE, Pimentel H, Sandler HM, et al. 
Long-term outcomes among localized prostate cancer survivors: health-related 
quality-of-life changes after radical prostatectomy, external radiation, and 
brachytherapy. J Clin Oncol (2005) 23:2772–80. doi:10.1200/JCO.2005.07.116 
31. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, 
et  al. Long-term functional outcomes after treatment for localized prostate 
cancer. N Engl J Med (2013) 368:436–45. doi:10.1056/NEJMoa1209978 
32. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Sturmer T, et al. Intensity-
modulated radiation therapy, proton therapy, or conformal radiation therapy 
and morbidity and disease control in localized prostate cancer. JAMA (2012) 
307:1611–20. doi:10.1001/jama.2012.460 
33. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et  al. 
Health-related quality of life after stereotactic body radiation therapy for 
localized prostate cancer: results from a multi-institutional consortium of pro-
spective trials. Int J Radiat Oncol Biol Phys (2013) 87:939–45. doi:10.1016/j.
ijrobp.2013.08.019 
34. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et  al. 
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis 
from a multi-institutional consortium of prospective phase II trials. Radiother 
Oncol (2013) 109:217–21. doi:10.1016/j.radonc.2013.08.030 
35. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, et al. 
Clinicopathologic analysis of extracapsular extension in prostate cancer: 
should the clinical target volume be expanded posterolaterally to account 
for microscopic extension? Int J Radiat Oncol Biol Phys (2006) 65:999–1007. 
doi:10.1016/j.ijrobp.2006.02.039 
36. Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A. Treatment 
of prostate cancer with radiotherapy: should the entire seminal vesicles be 
included in the clinical target volume? Int J Radiat Oncol Biol Phys (2002) 
54:686–97. doi:10.1016/S0360-3016(02)03011-0 
37. Liang J, Wu Q, Yan D. The role of seminal vesicle motion in target margin 
assessment for online image-guided radiotherapy for prostate cancer. Int 
J Radiat Oncol Biol Phys (2009) 73:935–43. doi:10.1016/j.ijrobp.2008.10.019 
38. Muralidhar V, Chen MH, Reznor G, Moran BJ, Braccioforte MH, 
Beard CJ, et al. Definition and validation of “favorable high-risk prostate 
cancer”: implications for personalizing treatment of radiation-managed 
patients. Int J Radiat Oncol Biol Phys (2015) 93:828–35. doi:10.1016/j.
ijrobp.2015.07.2281 
39. Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniau-
Alexandre E, et  al. Outcome according to elective pelvic radiation therapy 
in patients with high-risk localized prostate cancer: a secondary analysis of 
the GETUG 12 phase 3 randomized trial. Int J Radiat Oncol Biol Phys (2016) 
94:85–92. doi:10.1016/j.ijrobp.2015.09.020 
40. Lawton CA, DeSilvio M, Roach M III, Uhl V, Kirsch R, Seider M, et al. An 
update of the phase III trial comparing whole pelvic to prostate only radio-
therapy and neoadjuvant to adjuvant total androgen suppression: updated 
analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation 
interactions. Int J Radiat Oncol Biol Phys (2007) 69:646–55. doi:10.1016/j.
ijrobp.2007.04.003 
41. Katz A, Kang J. Stereotactic body radiotherapy with or without external beam 
radiation as treatment for organ confined high-risk prostate carcinoma: a six 
year study. Radiat Oncol (2014) 9:1. doi:10.1186/1748-717X-9-1 
Conflict of Interest Statement: SC and BC serve as clinical consultants to Accuray 
Inc. The Department of Radiation Medicine at Georgetown University Hospital 
receives a grant from Accuray to support a research coordinator. The other authors 
declare that they have no competing interests.
Copyright © 2016 Mercado, Kress, Cyr, Chen, Yung, Bullock, Lei, Collins, Satinsky, 
Harter, Suy, Dritschilo, Lynch and Collins. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License (CC BY). The use, 
distribution or reproduction in other forums is permitted, provided the original 
author(s) or licensor are credited and that the original publication in this journal 
is cited, in accordance with accepted academic practice. No use, distribution or 
reproduction is permitted which does not comply with these terms.
